The identification of functional driver events in cancer is central to furthering our understanding of cancer biology and indispensable for the discovery of the next generation of novel drug targets. It is becoming apparent that more complex models of cancer are required to fully appreciate the contributing factors that drive tumorigenesis in vivo and increase the efficacy of novel therapies that make the transition from preclinical models to clinical trials.
Introduction
Solid tumors display significant histological, genetic and micro-environmental intra-tumor heterogeneity, which presents clinicians with a significant challenge in being able to treat patients successfully. The majority of models used to identify novel targeted therapies do not incorporate many of these features. Indeed, current targeted therapies utilized in the clinic have been developed in the last decade employing screening approaches that rely on cancer cell lines grown under two-dimensional (2D) culture conditions. Although this has brought about various successes, such as receptor tyrosine kinase inhibitors, it is becoming apparent that more complex models of cancer are required to fully appreciate the contributing factors that drive tumorigenesis in vivo and increase the number of new therapies that make the transition from pre-clinical models to clinical trials. Moreover, it is now well appreciated that 2D culture systems fail to reflect in vivo behavior 1, 2 . For example, in poorly vascularized tumors, as the demand for oxygen and nutrients within the microenvironment outstrip supply, regions of high and low deliveries develop. The presence of low oxygen (hypoxia) in tumors, as detected by the immunohistochemical staining of tumor sections for established hypoxic markers such as carbonic anhydrase IX (CAIX), correlates with a poorer clinical outcome in breast cancer 3, 4 Thus incorporating features such as hypoxia into screening models may enhance our capacity to discover novel drug targets that will be more efficacious in vivo. Indeed, successfully targeting aggressive tumors that contain hypoxia is a clinical priority 5 .
The altering of traditional 2D siRNA screening, in an attempt to more accurately recapitulate elements of the conditions encountered by cancer cells in the tumor microenvironment, has led to the identification of several genes that have been found to be important for tumor growth in vivo. These include functional genomic screens performed under low serum conditions 6 , hypoxic conditions 7 and in combination 8 . For example, silencing of 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4 (PFKFB4), a protein responsible for regulating carbon entering glycolysis, only induced apoptosis in prostate cancer lines derived from metastasis when grown in low serum. Silencing of PFKFB4 in normal prostate cell lines under the same conditions had no effect, whereas, depletion of PFKFB4 completely ablated the growth of prostate cancer cell line xenografts 6 .
In an extended panel of breast cancer cell lines, the silencing of mono-carboxylase transporter 4 (MCT4) preferentially led to the reduction of cell line growth under conditions of low oxygen. This vulnerability was validated in vivo in breast cancer cell line orthotropic xenografts. Perhaps most strikingly, silencing of Acetyl-CoA synthetase 2 (ACSS2), an enzyme responsible for converting acetate into acetyl-CoA, reduced cancer cell number under nutrient stress conditions (low oxygen and serum) but had little or no effect under normal culture conditions . Furthermore, ACSS2 was also found to be important in glioblastoma and hepatocellular carcinomas 9, 10 , suggesting that increased ACSS2 activity in tumors could be a fundamental mechanism that supports growth under unfavorable conditions. Collectively, these studies prove that recapitulating the conditions encountered in vivo and performing siRNA screens allows for the identification of genes essential for cancer survival. As well as impacting 2D cancer cell growth under nutrient stress conditions, depletion of target genes in these studies inhibited cancer cell line spheroid growth, mirroring what was observed in tumor xenografts 6, 8 . Thus, cancer cell line spheroids contain several of the conditions encountered in the tumor microenvironment that impart sensitivity to ACSS2 silencing. Indeed, spheroids display nutrient gradients (Serum and oxygen), changes in pH, three-dimensional (3D) cell-cell contact, but also, alterations in proliferative celerity with cells undergoing cell cycle arrest and apoptosis. This is exemplified by the presence in cancer spheroids of necrotic regions, a feature not found in traditional 2D culture.
Cancer cell spheroids have already been used as more biologically relevant models to screen small molecule inhibitors but this only allows for the validation of compound efficacy or the repurposing of compounds originally design for other diseases 11 . Current spheroid screening methods do not allow for the analysis of specific gene depletion in a high-throughput of high-content manner. Here, we describe for the first time, a functional genomics pipeline for uncovering specific gene dependencies utilizing small interfering RNA (siRNA) technology in cancer cell line spheroids. We designed a bespoke library with siRNAs targeting the 200 most frequently mutated genes in human breast cancers and assessed the impact of gene depletion on spheroid size and metabolic activity in BT474 breast cancer spheroids. We were able to robustly and reproducibly detect the impact of ERBB2 and PIK3CA silencing in 3D cultures. Moreover, we could assess the impact of gene depletion on the spatial architecture of BT474 spheroids using immunohistochemistry.
Protocol

Preparation of 96-well siRNA Plates
NOTE: The outer edges of a 96-well plate are more prone to evaporation compared to other wells, thus limit the amount of siRNAs to 60 per 96-well plate. Fill in outer wells with plain medium or PBS to limit this. In addition, a validation screen of hits is recommended to alleviate plate biases.
1. Dilute the siRNAs to 250 -500 ng/μL in reduced serum medium (as per manufacturer's recommendations) and aliquot 10 μL to the appropriate wells of the ultra-low attachment plate. Perform all screens in triplicate. NOTE: Incorporate appropriate non-targeting (negative) and killing (positive, such as UBB and PLK1) siRNA controls in the plate design to ensure transfection efficiency can be assessed. The use of low-attachment plates for the siRNA work is critical, as cells will be added to the transfection mixture. We cannot rule out that some manufacturers ultra-low attachment plates may have subtle effects on spheroid growth. As such we recommend that these are tested by the end user. 2. Cover plates with adhesive seals and store at -20 °C.
Reverse Transfection of Cell Line
1. On the day of the screen, defrost the plates at room temperature and spin for 5 min at 1,000 x g using a bench-top centrifuge. Add 10 μL of reduced serum medium containing the optimized-transfection reagent to each well using a multichannel pipette. Leave plates for 15 min for transfection complexes containing siRNA to form. NOTE: This study utilized the breast cancer cell line BT474 for functional genomic screening (cultured in high glucose DMEM (Dulbecco's Modified Eagle Medium) supplemented with 10% fetal bovine serum (FBS) and antibiotics). 2. Trypsinize the cells to be screened (0.05% trypsin and 0.53 mM EDTA) until they detach from the flask, neutralize using appropriate volume of cell line specific medium and spin for 5 min at 1,000 x g on a bench-top centrifuge to remove trypsin. Resuspend cells with an appropriate volume of medium and determine accurate cell number using a cell counter. NOTE: Typically 5,000 cells per well are sufficient for spheroid formation across most cell lines tested. It is important to accurately count the cells as a single cell suspension for accurate size comparisons. 3. Dilute cells to 5,000 cells per 180 μL in cold medium (4 °C).
NOTE: The addition of reconstituted basement membrane matrix components will negatively impact transfection efficiency and it is recommended that it is not used. Cell line optimization to confirm spheroid forming capacity and knockdown efficacy should be performed prior to the screen. 4. Transfer the cell suspension to a reservoir, pipet to mix and add 180 µL to each well of the 96-well ultra-low attachment plate containing the siRNA prepared previously (2.1). 5. Centrifuge the plate at 1,000 x g in a precooled 4 °C centrifuge for 10 min and then return to a 37 °C tissue culture incubator. 6. NOTE: The cells will appear as a mosaic in the bottom of the wells. Over the next 12 -24 h the cells will aggregate together to form a single sphere. 7. After 24 h, observe the cells form a single spheroid in the center of the well. Add 100 µL of complete medium to each well to encourage growth. 8. Replenish medium after three days. Gently remove 100 µL of medium from each well and add 100 µL of fresh medium. 9. On day 7, quantify the automated spheroid size on a plate reader that can quantitatively monitor spheroid growth over time (see Section 3). 10 . Afterwards, determine cell viability using a luminescent cell viability dye (see Section 4). 11, 12 . NOTE: The spheroid area will then be calculated using the software algorithm. For example, to accurately calculate the area of BT474 spheroids grown for seven days adjust precision to 'high' and set the minimum colony diameter to 200 µM. This should produce an appropriate spheroid mask representative of the spheroid area. NOTE: These data can then be exported from the machine, using the export function, in in the form of an annotated data file. Date is plate median normalized, combined and analyzed either by z-score or strictly standardized mean difference (SSMD) to identify siRNAs that had a statistically significant effect on spheroid area.
Determining Cell Viability
1. After spheroid area has been calculated, determine the viability using a luminescent viability cell dye. Prepare the reagent as per the manufacturer's instructions. 2. Carefully remove 100 µL of medium from each well and add 100 µL of viability dye. Incubate plates for 15 min then scan using a luminescent plate reader. NOTE: These data can then be exported from the machine, using the export function, in in the form of an annotated data file. Date is plate median normalized, combined and analyzed either by z-score or strictly standardized mean difference (SSMD) to identify siRNAs that had a statistically significant effect on spheroid viability.
Representative Results
Spheroid assays in ultra-low attachment 96-well plates provide a high-throughput phenotypic assessment for potential oncogenicity in a context that more readily recapitulates the physiological conditions found in tumors in vivo. Indeed, the cancer cell lines MCF10DCIS.com and BT474 form tight spheroid structures ( Figure 1A) and immunohistological investigation of spheroid sections showed distinct spatial changes in cellular and nuclear morphology. Over time, some spheroids such as BT474 spheroids develop necrotic regions, a common feature of aggressive solid tumors (Figure 1B) . Some spheroids do not develop necrotic cores, such as the MDA-MB-231 cell line, but do display marked variation in the proliferative marker Ki67, which inversely correlates with cleaved caspsase-3 expression, a marker of apoptosis (Figure 1C) . To establish that multiple cell lines are indeed receptive to siRNA-mediated gene silencing BT474, MCF10DCIS.com, MDA-MB-231 and JIMT1 cells were reverse transfected with siRNA for seven days. The presence of transfection reagent (mock) or transfection of control siRNAs had no effect on spheroid viability, while silencing of the essential gene Ubiquitin B (UBB) significantly reduced spheroid viability in all the cell lines tested (Figure 1D) .
We designed a human siRNA library that encompassed the most frequently mutated genes in unselected, ER+, HER2+ and triple negative breast cancers. This library consists of genes of known function, such as MYC, PIK3CA and TP53 and those whose contribution to carcinogenesis is not established. The screen also contains several non-targeting control siRNAs (Control #1, Control #2) and siRNAs targeting essential genes, such as PLK1 and UBB, which act as killing controls ( Table 1) . We chose to use the breast cancer cell lines BT474 as they readily form spheroids without the addition of reconstituted basement membrane, are established workhorse cell lines and have a known genomic architecture. For example, BT474 cells are positive for the estrogen receptor (ER+), overexpress the human epidermal growth factor receptor 2 (HER2+) and harbor mutations in TP53 (E285K) and PIK3CA (K111N) 13 .
Employing the protocol outlined above, we monitored the impact gene depletion had on spheroid size and viability after seven days of siRNA reverse transfection (Figure 1E) . Interestingly, the majority of genes did not have a significant effect on spheroid area or viability (Figure 2A) . Silencing of FOXO3, PIK3CA, ERBB2 and SF3B1 resulted in the most significant reproducible reduction in spheroid size. This reduction was also observed in spheroid viability after ERBB2 and SF3B1 silencing. Encouragingly, we confirmed the impact of PIK3CA, ERBB2 and SF3B1 silencing on spheroid size using bright-field microscopy (Figure 2B) . We previously identified SF3B1 as an essential gene in numerous cell line models and thus siSF3B1 represents a good killing control in addition to UBB 1  2  3  4  5  6  7  8  9  10  11  12   Nontargeting 1   TP53  DST  KMT2C  Untreated  1   FCGBP  ARID1B  FBXM7  TTC40  Nontargeting 2   GATA3  TTN  MUC12  MUC4  AHNAK  HUWEI1  DNAH11  ITPR2  ABCA13  CREBBP   MAP2K4  PIK3CA  F5  APOB  ANKRD30A MUC17  DNAH17  LAMA2  ACE  CSMD2   STARD9  USH2A  FAT3  LPR2  CSMD3  MYO18B DNAH5  MDN1  ARHGAP5 DNAH9   CXCR3  MUC16  RB1  PKHD1L1 DNAH2  SYNE2  DYNC1H1 PCLO  CACNA1B ERBB2   PLK1  SYNE1  LYST  PTEN  SPTA1  Untreated  2   VHL  RYR1  COL6A3 ATR  DMXL2  MXRA5  ANK2  KIAA1210 PRUNE2 TCHH  DANH6  NOTCH2 ANKRD12   BIRC6  DNAH10  TENM1  ATM  LRP1  SCN10A  VPS13C  DNAH7  SPEN  C5ORF42   CDH1  DNAH3  PEG3  DIDO1  MAP1A  SCN2A  IPTR3  ERBB3  SRRM2  CCDC88A   CUBN  NOCK11  RELN  DNAH8  MED12  SHROOM2 CEP350  FAT4  SZT2  CHD4   PLK1  EYS  SACS  KIAA1109 MED13  Untreated  2   VHL  KMT2A  VPS13A  UBB   1  2  3  4  5  6  7  8  9  10  11  12 Nontargeting 
Discussion
Three-dimensional models of cancer are being increasingly employed to evaluate the efficacy of known and novel compounds that have been designed to selectively kill cancer cells. Cancer cell spheroids are structures that display conditions more similar to those encountered in tumors in vivo, thus compounds that have increased efficacy in 3D are more likely to have an effect in vivo. However, these modalities do not allow for the identification of potentially novel targets that have not been the subject of drug design that could have considerable efficacy in treating cancer.
We developed a siRNA functional genomics approach that allowed for durable gene silencing for up to seven days in cancer cell line spheroids.
There are several critical steps to the protocol that require optimization before a siRNA screen can be performed. several different transfection reagents with appropriate non-targeting and killing controls prior to attempting the screen. We were able to show that several commonly used breast cancer cell lines, namely BT474, MCF10DCIS.com, MDA-MB-231 and JIMT1 were amenable to siRNA transfection. Furthermore, we provide proof-of-principle data screening the 200 most frequently mutated genes in breast cancer in BT474 spheroids, confirmed their dependency on amplification of HER2 and oncogenic mutation of PIK3CA. Interestingly, silencing of the transcription factor FOXO3 resulted in a reduction in spheroid size but no significant effect on viability. FOXO3 is known to regulate the response to hypoxia, altering the metabolic capacity of cancer cells allowing them to adapt more readily to their environment 16 . This role could potentially interfere with the cell viability reading as it detects ATP abundance, one of the main products of cell metabolism.
In support of the observation of a reduction in spheroid size, it has been shown that silencing of FOXO3 in HeLa xenografts impaired tumor growth and induced apoptosis 17 . It is important to note that some genes may impact the capacity of cancer cells to retain their 3D architecture, which could result in false positives. For example, knockdown of E-Cadherin resulted in dissolution of BT474 spheroid structure. This had been previously reported using E-Cadherin targeted antibodies 18 . As with any screening platform, potential targets should be rescreened to assess the reproducibility of the effect observed. There are limitations to the technique, namely the transient nature of the siRNA-mediated gene knockdown. Sustained silencing longer than seven days was not achievable with siRNA.
The advantage of this approach is that it can be coupled with various other biometric dyes not just those that assess spheroid viability, for example, giving spatial information of spheroid hypoxia or monitoring cells undergoing apoptosis. Moreover, because the plate reader scans are relatively quick and non-invasive, the impact of siRNAs on spheroid size can be assessed over time rather than just at the experimental end point. Indeed, we are currently exploring several of these avenues within our screening pipeline. An alternative approach that utilizes 3D cultures to identify novel dependencies is the use of chemical libraries that inhibit either a broad range of targets or particular families of proteins. Indeed, Bitler et al. utilized this targeted approach to identify the synthetic lethality interaction between ARID1A status and EZH2 inhibitors in ovarian clear cell carcinomas 19 . The discovery of CRISPR-Cas9 gene editing technology has also allowed for the development of genetic screens in organoid cultures and in vivo. However, this approach is dependent on having appropriate animal facilities and may be cost prohibitive 20 .
In conclusion, we believe that we have outlined a protocol that more accurately models the oxygen and nutrient gradients, which are features of the tumor microenvironment in vivo, allowing for the identification of novel cancer targets or robust validation of established targets. Moreover, our protocol can be applied to any type of cell line that forms spheroids and hence can be routinely used in the cancer research community for high-throughput siRNA screens.
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